modelVigabatrin
Extends from Pharmacolibrary.Drugs.ATC.N.N03AG04.
Information
| name: | Vigabatrin | |
| ATC code: | N03AG04 | route: | oral |
| compartments: | 1 | |
| dosage: | 1000 | mg |
| volume of distribution: | 0.8 | L |
| clearance: | 7 | L/h |
| other parameters in model implementation | ||
Vigabatrin is an antiepileptic drug used as adjunctive therapy in the treatment of refractory complex partial seizures and as monotherapy for infantile spasms (West syndrome). It is an irreversible inhibitor of gamma-aminobutyric acid transaminase (GABA-T), increasing GABA levels in the brain. Approved and in use today in several countries, though usually reserved for refractory cases due to the risk of irreversible visual field defects.
Pharmacokinetics
Healthy adult volunteers, single or repeated oral doses, both sexes, various studies.
References
Jacob, S, & Nair, AB (2016). An Updated Overview on Therapeutic Drug Monitoring of Recent Antiepileptic Drugs. Drugs in R&D 16(4) 303–316. DOI:10.1007/s40268-016-0148-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27766590
Nøhr, MK, et al., & Nielsen, CU (2015). Is oral absorption of vigabatrin carrier-mediated?. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 69 10–18. DOI:10.1016/j.ejps.2014.12.018 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25562534
Yu, DK, et al., & Weir, SJ (1994). A comparison of population and standard two-stage pharmacokinetic analyses of vigabatrin data. Biopharmaceutics & drug disposition 15(6) 473–484. DOI:10.1002/bdd.2510150605 PUBMED:https://pubmed.ncbi.nlm.nih.gov/7993985
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)